Shiven B. Patel

968 total citations
47 papers, 420 citations indexed

About

Shiven B. Patel is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Shiven B. Patel has authored 47 papers receiving a total of 420 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 24 papers in Pulmonary and Respiratory Medicine and 9 papers in Molecular Biology. Recurrent topics in Shiven B. Patel's work include Cancer Immunotherapy and Biomarkers (15 papers), Lung Cancer Treatments and Mutations (9 papers) and Lung Cancer Research Studies (8 papers). Shiven B. Patel is often cited by papers focused on Cancer Immunotherapy and Biomarkers (15 papers), Lung Cancer Treatments and Mutations (9 papers) and Lung Cancer Research Studies (8 papers). Shiven B. Patel collaborates with scholars based in United States, United Kingdom and Spain. Shiven B. Patel's co-authors include Wallace Akerley, Kenneth F. Grossmann, Sarah V. Colonna, John Hyngstrom, A. Chalmers, David Gill, Benjamin Haaland, David D. Stenehjem, Justin C. Moser and Archana M. Agarwal and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Shiven B. Patel

41 papers receiving 417 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shiven B. Patel United States	12	276	168	106	61	46	47	420
Melinda Laine Hsu United States	11	214 0.8×	119 0.7×	160 1.5×	111 1.8×	25 0.5×	28	422
Yong Mun United States	11	313 1.1×	115 0.7×	132 1.2×	33 0.5×	15 0.3×	43	464
Rabih Said United States	11	153 0.6×	105 0.6×	118 1.1×	29 0.5×	44 1.0×	33	390
Enzo Veltri Italy	10	353 1.3×	150 0.9×	71 0.7×	37 0.6×	11 0.2×	13	421
Won Jin Chang South Korea	12	177 0.6×	110 0.7×	79 0.7×	23 0.4×	16 0.3×	27	353
Karl Verpoort Germany	7	222 0.8×	53 0.3×	64 0.6×	123 2.0×	65 1.4×	10	370
Rumiko Okamoto Japan	10	244 0.9×	73 0.4×	105 1.0×	31 0.5×	23 0.5×	27	488
Kelsey Klute United States	8	166 0.6×	64 0.4×	128 1.2×	24 0.4×	15 0.3×	26	348
Sonam Puri United States	12	324 1.2×	176 1.0×	149 1.4×	67 1.1×	11 0.2×	64	517
Gary W. Jean United States	7	239 0.9×	92 0.5×	78 0.7×	80 1.3×	9 0.2×	14	375

Countries citing papers authored by Shiven B. Patel

Since Specialization

Citations

This map shows the geographic impact of Shiven B. Patel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shiven B. Patel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shiven B. Patel more than expected).

Fields of papers citing papers by Shiven B. Patel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shiven B. Patel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shiven B. Patel. The network helps show where Shiven B. Patel may publish in the future.

Co-authorship network of co-authors of Shiven B. Patel

This figure shows the co-authorship network connecting the top 25 collaborators of Shiven B. Patel. A scholar is included among the top collaborators of Shiven B. Patel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shiven B. Patel. Shiven B. Patel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cheng, Ying, Xiao‐Chen Zhang, Jian Liu, et al.. (2024). YL202/BNT326, a HER3-targeted ADC, in patients with locally advanced or metastatic non-small cell lung cancer and breast cancer: Preliminary results from a first-in-human phase I trial.. Journal of Clinical Oncology. 42(16_suppl). 3034–3034. 5 indexed citations

Neal, Joel W., Armando Santoro, María González‐Cao, et al.. (2024). Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study. JTO Clinical and Research Reports. 5(10). 100666–100666. 2 indexed citations

Jo, Yeonjung, Sonam Puri, Benjamin Haaland, et al.. (2024). Augmenting Prognostication: Utilizing Activity Trackers to Enhance Survival Prediction in Metastatic Non-Small Cell Lung Cancer. Clinical Lung Cancer. 26(1). 29–38.

Sinnott, Jennifer A., et al.. (2023). Real-world comparison of survival outcomes with cisplatin versus carboplatin in patients with limited-stage small-cell lung cancer. Cancer Treatment and Research Communications. 35. 100686–100686. 3 indexed citations

Patel, Shiven B., et al.. (2023). Synergistic Toxicities from Multiple Therapies for Synchronous Malignancies. SHILAP Revista de lepidopterología. 45–48.

Mansfield, Aaron S., Penelope A. Bradbury, David J. Kwiatkowski, et al.. (2023). OA02.04 Phase 1/2 Randomized Trial of Anetumab Ravtansine and Pembrolizumab Compared to Pembrolizumab for Pleural Mesothelioma - NCT03126630. Journal of Thoracic Oncology. 18(11). S47–S47. 2 indexed citations

Puri, Sonam, Rachna Malani, A. Chalmers, et al.. (2023). Keeping a track on leptomeningeal disease in non–small cell lung cancer: A single-institution experience with CNSideTM. Neuro-Oncology Advances. 6(1). vdad150–vdad150. 3 indexed citations

Puri, Sonam, Abdul Rafeh Naqash, Andrew Elliott, et al.. (2021). Real-world multiomic characterization of small cell lung cancer subtypes to reveal differential expression of clinically relevant biomarkers.. Journal of Clinical Oncology. 39(15_suppl). 8508–8508. 11 indexed citations

Chipman, Jonathan, Yeonjung Jo, Benjamin Haaland, et al.. (2021). OA09.05 Real-World Survival Outcomes of Patients with Malignant Pleural Mesothelioma by Physician’s Choice of First-line Platinum Chemotherapy. Journal of Thoracic Oncology. 16(3). S122–S123.

10.

Neal, Joel W., Farah Louise Lim, Enriqueta Felip, et al.. (2020). Cabozantinib in combination with atezolizumab in non-small cell lung cancer (NSCLC) patients previously treated with an immune checkpoint inhibitor: Results from cohort 7 of the COSMIC-021 study.. Journal of Clinical Oncology. 38(15_suppl). 9610–9610. 28 indexed citations

11.

Patel, Shiven B., Benjamin Haaland, Dominik Ose, et al.. (2020). Prognostic Significance of Patient-Reported Outcomes in Cancer. JCO Oncology Practice. 16(4). e313–e323. 42 indexed citations

12.

Chalmers, A., et al.. (2019). Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long-Term Follow-Up. Targeted Oncology. 14(4). 417–421. 40 indexed citations

13.

Kim, Hyeon Woo, Kimberly Harrow, Giovanni Selvaggi, et al.. (2019). P1.14-57 Post-Ensartinib Outcomes in Refractory Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 14(10). S577–S578.

14.

Ponce, Santiago, Shiven B. Patel, C. van Herpen, et al.. (2019). P1.01-113 Phase 1b Trial of Cabozantinib or Cabozantinib Plus Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 14(10). S405–S406. 1 indexed citations

15.

Chen, Danli, Siwen Hu‐Lieskovan, Kenneth F. Grossmann, et al.. (2019). Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab. Cancer Medicine. 8(18). 7637–7643. 39 indexed citations

16.

Patel, Shiven B., Wallace Akerley, Dominik Ose, et al.. (2018). Prognostic value of patient-reported outcomes (PROs) in advanced cancer.. Journal of Clinical Oncology. 36(30_suppl). 8–8. 1 indexed citations

17.

McPherson, Jordan P., et al.. (2018). Real-time assessment of resource utilization and subsequent cost analysis in cancer patients (pts) near the end of life (EOL).. Journal of Clinical Oncology. 36(30_suppl). 303–303. 6 indexed citations

18.

Garrido‐Laguna, Ignacio, Shiven B. Patel, & David Gill. (2015). Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer. OncoTargets and Therapy. 9. 75–75. 6 indexed citations

19.

Patel, Shiven B., David D. Stenehjem, David Gill, et al.. (2015). Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic Therapies. Clinical Genitourinary Cancer. 14(2). 153–159. 10 indexed citations

20.

Patel, Shiven B., Ivana Gojo, Michael L. Tidwell, Edward A. Sausville, & Maria R. Baer. (2011). Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy. Leukemia & lymphoma. 52(7). 1211–1214. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact